Opinion statement
Taking steps to minimize, prevent, and treat infection in patients with chronic lymphoid malignancies, especially chronic lymphocytic leukemia, has always been a challenge. As more patients with these diseases live longer and lead productive lives upon successful initial treatment, strategies for preventing infections havebecome more important. Distinguishing patients at low risk for infection from those at high risk is a crucial but challenging issue.
Unfortunately, there are hardly any data on the use of prophylactic antibiotics for patients with chronic lymphoid malignancy (CLL). If patients cannot be enrolled in a clinical trial, antibiotics with co-trimoxazole should be administered when steroids are warranted. They should also be administered in patients who have had a documented infection early in the treatment course and during neutropenia.
Viral infections remain another controversial issue in patients with CLL receiving treatment, especially a purine analogue. Very low CD4 counts (less than 50 cells/mL) might predict for reactivation for herpes zoster. Outside of depleted CD4 counts, there are no other means of identifying a high-risk group. Based on limited data, it would be reasonable to administer herpes zoster prophylaxis to patients with CD4 counts that are severely depleted or to patients with a prior episode of zoster.
Controversial issues still remain regarding immunoglobulin treatment, specifically cost, scarcity of the product, and adequate dose, which has not yet been established. We would consider intravenous immunoglobulin (Ig) replacement in patients with marked hypogammaglobulinemia IgG less than 400 mg/dL with more than two recent severe infections [1]. Lower Ig doses 240 mg/kg have been shown to be equivalent to higher ones in this trial [1].
Similar content being viewed by others
References and Recommended Reading
Chapel H, Dicato M, Gamm H, et al.: Immunoglobulin replacement in patients with chronic lymphocytic leukaemia: a comparison of two dose regimens. Br J Haematol 1994, 88:209–212.
Apostopoulos A, Simeonidis A, Zoumbos N: Prognostic significance of immune function parameters in patients with chronic lymphocytic leukemia. Eur J Haematol 1990, 44:39–44.
Dighiero G: Hypogammaglobulinemia and disordered immunity in CLL. In Chronic Lymphocytic Leukemia. Scientific Advances and Clinical Developments. Edited by Cheson BD. New York: Dekker; 1993:147–166.
Itälä M, Helenius H, Nikoskelaien J, et al.: Infections and serum IgG levels in patients with chronic lymphocytic leukemia. Eur J Haematol 1992, 48:266–270.
Ross SC, Densen P: Complement deficiency states and infection: epidemiology, pathogenesis and consequences of neisserial and other infections in immune deficiency. Medicine (Baltimore) 1984, 63:243–273.
Morrison VA: The infectious complications of chronic lymphocytic leukemia. Semin Oncol 1998, 25:98–106. A comprehensive and well-summarized review article.
Morris PJ, Cooper IA, Madigan JP: Splenectomy for hematological cytopenias in patients with malignant lymphomas. Lancet 1986, 2:250–253.
Molica S: Infections in chronic lymphocytic leukemia: risk factors and impact on survival and treatment. Leuk Lymphoma 1994, 13:203–214.
Chu M, Brown AE, Blevins A, et al.: Severe pneumococcal infection in patients with neoplastic disease. Cancer 1983, 51:1546–1550.
Anaissie EJ, Kontoyannis D, O’Brien S, et al.: Infections in patients with chronic lymphocytic leukemia treated with Fludarabine. Ann Intern Med 1998, 129:559–566.
O’Brien S, Kantarjian H, Beran M, et al.: Results of fludarabine and prednisone therapy in 264 patients with chronic lymphocytic leukemia with multivariate analysis-derived prognostic model for response to treatment. Blood 1993, 82:1695–1700.
Cooperative Group for the Study of Immunoglobulin in Chronic Lymphocytic Leukemia: Intravenous immunoglobulin for the prevention of infection in chronic lymphocytic leukemia. A randomized, controlled clinical trial. N Engl J Med 1988, 319:902–907.
Weeks JC, Tierney MR, Weinstein MC: Cost effectiveness of prophylactic intravenous immune globulin in chronic lymphocytic leukemia. N Engl J Med 1991, 325:81–86.
O’Brien S, Kantarjian H, Beran M, et al.: Fludarabine and granulocyte colony-stimulating factor (G-CSF) in patients with chronic lymphocytic leukemia. Leukemia 1997, 11:1631–1635. Patients treated with purine analogues and G-CSF were compared with a historical control group.
Jacobson DR, Ballard HS, Silber R, et al.: Antibody response in pneumococcal immunization in patients with chronic lymphocytic leukemia. Blood 1988, 72(suppl):205a.
Karthaus M, Wolf HH, Kampfe D, et al.: Ceftriaxone monotherapy in the treatment of low-risk febrile neutropenia. Chemotherapy 1998, 44:343–354.
Pizzo PA: Management of fever in patients with cancer and treatment-induced neutropenia. N Engl J Med 1993, 328:1323–1232.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Egerer, G., Hensel, M. & Ho, A.D. Infectious complications in chronic lymphoid malignancy. Curr. Treat. Options in Oncol. 2, 237–244 (2001). https://doi.org/10.1007/s11864-001-0037-1
Issue Date:
DOI: https://doi.org/10.1007/s11864-001-0037-1